Clinical trials: Adenocarcinoma of the Prostate
Ischemic Heart Disease, Prostate Adenocarcinoma
Ischemic Heart Disease in Male With Prostate Adenocarcinoma
The purpose of the study: to increase the efficiency of diagnosis, treatment and prediction of the course of coronary heart disease in patients with adenocarcinoma of the prostate gland, depending on the hormonal status by…
- Trial name
- NCT03474835
- Testing
- ISCHEMIC HEART DISEASE diagnostic
- Where
- Ukraine
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Dnipropetrovsk State Medical Academy
Breast Cancer, Lung Cancer
Study to Evaluate Combination Treatment of MGCD0103 and Docetaxel (Taxotere®) for Subjects With Advanced Cancer Tumors
The purpose of this study is to test the combination of an experimental drug known as MGCD0103 given along with an FDA-approved drug called docetaxel.
- Conditions
- Breast Cancer, Lung Cancer, Pulmonary Cancer, Non-Small-Cell Lung Carcinoma
- Trial name
- NCT00511576
- Testing
- MGCD0103 & Docetaxel
- Where
- 2 sites in United States
- Volunteers
- 54 people
- Sponsor
- Mirati Therapeutics Inc.
Prostate Cancer
GM-CSF and Thalidomide in Treating Patients Undergoing Surgery for High-Risk Prostate Cancer
RATIONALE: Biological therapies, such as GM-CSF, may stimulate the immune system in different ways and stop tumor cells from growing. Thalidomide may stop the growth of prostate cancer by blocking blood flow to the tumor.
- Trial name
- NCT00400517
- Testing
- sargramostim, thalidomide, conventional surgery
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- The Cleveland Clinic
Prostate Cancer Metastatic
A Study of ARV-766 Given by Mouth in Men With Metastatic Prostate Cancer
This first-in-human, Phase 1/2, open-label study evaluates the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of JSB462 (luxdegalutamide, previously ARV-766) administered as monotherapy and in…
- Trial name
- NCT05067140
- Testing
- ARV-766, Abiraterone, Corticosteroid (e.g., prednisone/prednisolone)
- Where
- 17 sites in United States
- Volunteers
- 164 people
- Sponsor
- Novartis Pharmaceuticals
Prostate Cancer (Adenocarcinoma)
The Value of GRPR PET Imaging for Diagnosis and Staging in Prostate Cancer
The gastrin-releasing peptide receptor (GRPR) is highly expressed in prostate cancer (77%-100%). Numerous studies have confirmed that GRPR PET imaging has emerged as a significant molecular imaging modality in prostate cancer…
- Trial name
- NCT07363382
- Testing
- 68Ga-G21, 68Ga-G23
- Where
- China
- Volunteers
- 6 people
- Sponsor
- First Affiliated Hospital of Fujian Medical University
Prostate Cancer, Breast Cancer
Measuring Oncological Value of Exercise and Statin
The aim of the study is to find out whether supervised physical exercise during cancer drug treatment improves the effectiveness of the treatment in metastasized breast, kidney, ovarian and prostate cancer compared to…
- Conditions
- Prostate Cancer, Breast Cancer, Kidney Cancer, Ovarian Cancer
- Trial name
- MOVES (NCT05796973)
- Testing
- Guided physical exercise, Atorvastatin, Independent exercise
- Where
- Finland
- Volunteers
- 240 people
- Sponsor
- Tampere University Hospital
Adenocarcinoma of Prostate, Radical Prostatectomy
Multimodal Machine Learning Characterization of Solid Tumors
This research study wants to develop advanced imaging methods to more accurately characterize prostate cancer or solid tumor aggressiveness.
- Conditions
- Adenocarcinoma of Prostate, Radical Prostatectomy, Hepatocellular Carcinoma (HCC), Glioma
- Trial name
- NCT04687969
- Testing
- [18F]DCFPyL, PET/MRI scanner
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Ciprian Catana, MD, PhD
Prostate Cancer
Selenomethionine and Finasteride Before Surgery or Radiation Therapy in Treating Patients With Stage I or Stage II Prostate Cancer
RATIONALE: Selenomethionine may slow the growth of prostate cancer. Testosterone can cause the growth of prostate cancer cells. Finasteride may fight prostate cancer by lowering the amount of testosterone the body makes.
- Trial name
- NCT00736645
- Testing
- selenomethionine, finasteride
- Where
- United States
- Volunteers
- 55 people
- Sponsor
- Roswell Park Cancer Institute
Adenocarcinoma of the Prostate, Hormone-resistant Prostate Cancer
Linsitinib in Treating Patients With Asymptomatic or Mildly Symptomatic Metastatic Prostate Cancer
This phase II trial studies how well linsitinib works in treating patients with asymptomatic or mild symptomatic metastatic prostate cancer.
- Conditions
- Adenocarcinoma of the Prostate, Hormone-resistant Prostate Cancer, Recurrent Prostate Cancer, Stage IV Prostate Cancer
- Trial name
- NCT01533246
- Testing
- linsitinib, laboratory biomarker analysis
- Where
- 2 sites in United States
- Volunteers
- 17 people
- Sponsor
- National Cancer Institute (NCI)
Nonmalignant Neoplasm, Prostate Cancer
MRI and Magnetic Resonance Spectroscopy Imaging in Patients Receiving Dutasteride for Benign Prostatic Hypertrophy and Low-Risk Prostate Cancer
RATIONALE: Diagnostic procedures, such as MRI and magnetic resonance spectroscopy imaging, may help in learning how well dutasteride works in patients with benign prostatic hypertrophy and low-risk prostate cancer.
- Trial name
- NCT00706966
- Testing
- dutasteride
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- University of California, San Francisco
Adenocarcinoma of the Prostate
Muscadine Plus (MPX) In Men With Prostate Cancer
This research is being done to determine if men with rising PSA after initial therapy for localized prostate cancer who display the Alanine/Alanine SOD2 genotype of MnSOD and supplement their diet with MPX have greater decrease…
- Trial name
- NCT03535675
- Testing
- Muscadine Plus
- Where
- 13 sites in United States
- Volunteers
- 59 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Castration-Sensitive Prostate Carcinoma, Metastatic Prostate Adenocarcinoma
Vudalimab (XmAb20717) in Combination With Standard of Care Treatment in Patients With Metastatic Castration Sensitive Prostate Cancer
This phase I trial tests the safety and effectiveness of vudalimab (XmAb20717) in combination with standard of care treatment abiraterone, enzalutamide, or abiraterone plus docetaxel in treating patients with castration sensitive…
- Conditions
- Castration-Sensitive Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8
- Trial name
- NCT05733351
- Testing
- Abiraterone, Biospecimen Collection, Bone Scan
- Where
- 2 sites in United States
- Volunteers
- 4 people
- Sponsor
- Emory University
Prostate Cancer
Prostate Advances in Comparative Evidence
This study is an international multicentre randomised study of low, intermediate, and high risk prostate cancer and is composed of three parallel randomisation schemes based on applicability of surgery as a treatment for the…
- Trial name
- PACE (NCT01584258)
- Testing
- Prostatectomy, Conventionally Fractionated Prostate Radiotherapy, Prostate SBRT
- Where
- 68 sites in Canada, Ireland and 2 more
- Volunteers
- 2,205 people
- Sponsor
- Royal Marsden NHS Foundation Trust
Adenocarcinoma of the Prostate
The Prostate Immobilization Device Study
The purpose of this study is to compare reproducibility of the device position and location of the prostate rectum interface between two immobilization devices for radiation therapy of prostate carcinoma.
- Trial name
- NCT01408706
- Testing
- Miller Air tip, Radiadyne Immobilizer
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- James Taylor
Prostate Cancer, Radiation Toxicity
Radiation Therapy Plus Amifostine in Treating Patients With Primary Prostate Cancer
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Amifostine may protect normal cells from the side effects of radiation therapy.
- Trial name
- NCT00003307
- Testing
- amifostine trihydrate, radiation therapy
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- University of Arizona
Prostate Cancer (Adenocarcinoma), Prostate Cancer Metastatic Castration-Resistant
Sacituzumab Tirumotecan in Combination With Tagitanlimab in the Treatment of Aggressive Variant Prostate Cancer (AVPC) and Neuroendocrine Prostate Cancer (NEPC)
This study is a prospective, single arm II clinical trial. The main objective of the study is to evaluate the efficacy and safety of the combination of Sacituzumab Tirumotecan (SKB264) and Tagitanlimab (KL-A167) in the treatment…
- Conditions
- Prostate Cancer (Adenocarcinoma), Prostate Cancer Metastatic Castration-Resistant, Prostate Adenocarcinoma With Neuroendocrine Differentiation
- Trial name
- NCT07179783
- Testing
- Sacituzumab Tirumotecan, Tagitanlimab
- Where
- China
- Volunteers
- 28 people
- Sponsor
- Tianjin Medical University Second Hospital
Prostate Cancer (Adenocarcinoma), Prostate Cancer (Diagnosis)
Development of an Intraoperative Adaptive Biopsy System for Prostate Cancer: Integrating Imaging Navigation With Metabolic Feedback for Dynamic Decision-Making
Development of an Intelligent System Integrating Preoperative Imaging and Real-Time Intraoperative Metabolic Feedback to Dynamically Optimize Biopsy core Placement for Individualized Precision Sampling.
- Trial name
- NCT07856017
- Where
- 4 sites in China
- Volunteers
- 90 people
- Sponsor
- Shanghai Zhongshan Hospital
Bone Metastasis
Evaluation of Sodium Fluoride PET in the Identification of Bone Metastases in Patients Having Undergone a Choline PET for Occult Recurrence of Prostatic Adenocarcinoma
The purpose is to evaluate if sodium fluoride PET in patients having already undergone a choline PET negative for bone extension (non-metastatic status) modifies the status of patients concerning the existence or not of bone…
- Trial name
- FNa-CHOLINE (NCT02876991)
- Testing
- Sodium fluoride PET
- Where
- France
- Volunteers
- 110 people
- Sponsor
- Central Hospital, Nancy, France
Adenocarcinoma of the Prostate, Prostate Cancer
Pre-Prostatectomy Celecoxib or Placebo
This study will seek to determine if the downstream effects of cyclooxygenase-2 (COX-2) inhibition suggested by preclinical systems occur in human prostate cancer.
- Trial name
- NCT02840162
- Testing
- Celecoxib
- Where
- 2 sites in United States
- Volunteers
- 34 people
- Sponsor
- OHSU Knight Cancer Institute
Prostate Cancer
Interstitial Brachytherapy With or Without External-Beam Radiation Therapy in Treating Patients With Prostate Cancer
RATIONALE: Radiation therapy uses high-energy x-rays and other sources to damage tumor cells. Interstitial brachytherapy uses radioactive material placed directly into or near a tumor to kill tumor cells.
- Trial name
- NCT00063882
- Testing
- Brachytherapy (100/110), Brachytherapy (125/145), External Beam Radiation Therapy
- Where
- 170 sites in United States, Canada
- Volunteers
- 588 people
- Sponsor
- Radiation Therapy Oncology Group